



## Supporting Information

### **synthesis and evaluation of WK-X-34 derivatives as P-glycoprotein (P-gp/ABCB1) inhibitors for reversing multidrug resistance**



Fei Cao<sup>a, b</sup>, Yulong Li<sup>c</sup>, Furong Ma<sup>c</sup>, Zumei Wu<sup>c</sup>, Zheshen Li<sup>d</sup>, Zhe-Sheng Chen<sup>d</sup>, Xiangdong Cheng<sup>a, e, \*</sup>,  
Jiang-Jiang Qin<sup>a, e, \*</sup>, Jinyun Dong<sup>a, e, \*</sup>

- a. Zhejiang Cancer Hospital, Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Hangzhou 310022, China
- b. College of Pharmaceutical Science, Zhejiang University of Technology, Hangzhou 310032, China
- c. School of Pharmaceutical Sciences, Zhejiang Chinese Medical University, Hangzhou 310053, China
- d. College of Pharmacy and Health Sciences, St. John's University, Queens, NY, 11439, USA.
- e. Key Laboratory of Prevention, Diagnosis and Therapy of Upper Gastrointestinal Cancer of Zhejiang Province, Hangzhou 310022, China



**Methyl 4-((2-((4-(2-(6,7-dimethoxy-3,4-dihydroisoquinolin-2(1*H*)-yl)ethyl)phenyl)carbamoyl)phenyl)carbamoyl)benzoate (PID-1)**





**2-Amino-N-(2-((4-(2-(6,7-dimethoxy-3,4-dihydroisoquinolin-2(1H)-yl)ethyl)phenyl)carbamoyl)phenyl)benzamide (PID-2)**





**2-(4-Aminobenzamido)-N-(4-(2-(6,7-dimethoxy-3,4-dihydroisoquinolin-2(1H)-yl)ethyl)phenyl)benzamide (PID-3)**





**4-((2-((4-(2-(6,7-Dimethoxy-3,4-dihydroisoquinolin-2(1H)yl)ethyl)phenyl)carbamoyl)phenyl)carbamoyl)benzoic acid (PID-4)**





**2-(2-(Adamantan-1-yl)acetamido)-N-(4-(2-(6,7-dimethoxy-3,4-dihydroisoquinolin-2(1H)-yl)ethyl)phenyl)benzamide (PID-5)**



# 2-(3-(2-(adamantan-1-yl)acetamido)propanamido)-N-(4-(2-(6,7-dimethoxy-3,4-dihydroisoquinolin-2(1H)-yl)ethyl)phenyl)benzamide (PID-6)





***N*-((4-(2-(6,7-dimethoxy-3,4-dihydroisoquinolin-2(1*H*)-yl)ethyl)phenyl)carbamoyl) phenyl)adamantane-1-carboxamide (PID-7)**









**2-(4-(2-(adamantan-1-yl)acetamido)benzamido)-N-(4-(2-(6,7-dimethoxy-3,4-dihydroisoquinolin-2(1H)-yl)ethyl)phenyl)benzamide (PID-8)**



**2-(4-(4-(2-((1S,3s)-adamantan-1-yl)acetyl)piperazine-1-carbonyl)benzamido)-N-(4-(2-(6,7-dimethoxy-3,4-dihydroisoquinolin-2(1H)-yl)ethyl)phenyl)benzamide (PID-9)**




***N*<sup>1</sup>-(2-(2-((1*S*,3*S*)-adamantan-1-yl)acetamido)ethyl)-*N*<sup>4</sup>-(2-((4-(2-(6,7-dimethoxy-3,4-dihydroisoquinolin-2(1*H*)-yl)ethyl)phenyl)carbamoyl)phenyl)terephthalamide (PID-10)**




## PID-1

8 #40 RT: 0.11 AV: 1 NL: 2.04E9  
T: FTMS + p ESI Full ms [100.0000-1500.0000]




## PID-2

9 #45 RT: 0.11 AV: 1 NL: 1.81E9  
T: FTMS + p ESI Full ms [100.0000-1500.0000]




## PID-3


10 #38 RT: 0.10 AV: 1 NL: 2.10E9  
T: FTMS + p ESI Full ms [100.0000-1500.0000]




## PID-4




### PID-5




### PID-6




### PID-7



### PID-8



### PID-9



### PID-10

